{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:10:46Z","timestamp":1790172646067,"version":"4.1.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2015\/694"],"award-info":[{"award-number":["CAN 2015\/694"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2015-02844"],"award-info":[{"award-number":["2015-02844"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hudfonden (SE)","award":["2558"],"award-info":[{"award-number":["2558"]}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS 6844391"],"award-info":[{"award-number":["SLS 6844391"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["161052"],"award-info":[{"award-number":["161052"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN2014-424"],"award-info":[{"award-number":["CAN2014-424"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","award":["160502"],"award-info":[{"award-number":["160502"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2016fobi50190"],"award-info":[{"award-number":["2016fobi50190"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009734","name":"Alex och Eva Wallstr\u00f6ms Stiftelse f\u00f6r Vetenskaplig Forskning och Utbildning","doi-asserted-by":"publisher","award":["2018-00222"],"award-info":[{"award-number":["2018-00222"]}],"id":[{"id":"10.13039\/501100009734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["144073"],"award-info":[{"award-number":["144073"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["D0322301"],"award-info":[{"award-number":["D0322301"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["150574"],"award-info":[{"award-number":["150574"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["Dnr KAW 2013.0093"],"award-info":[{"award-number":["Dnr KAW 2013.0093"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["LS2015-1198"],"award-info":[{"award-number":["LS2015-1198"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0206942","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T13:39:50Z","timestamp":1541511590000},"page":"e0206942","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-3375","authenticated-orcid":true,"given":"Fernanda Costa","family":"Svedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-1693","authenticated-orcid":true,"given":"Warangkana","family":"Lohcharoenkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bottai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne Egyhazi","family":"Brage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enik\u00f6","family":"Sonkoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andor","family":"Pivarcsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"FS Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"ref2","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"KT Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"9839","key":"ref4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"A Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previoulsly untreated melanoma without BRAF mutation","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"6892","key":"ref7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"H Davies","year":"2002","journal-title":"Nature"},{"issue":"20","key":"ref8","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"J Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"9992","key":"ref9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a muticentre, double-blind, phase 3 radomised controlled trial","volume":"386","author":"GV Long","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00018-011-0689-3","article-title":"Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles","volume":"68","author":"B Gy\u00f6rgy","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737159.2014.893828","article-title":"Emerging technologies in extracellular vesicle-based molecular diagnostics","volume":"14","author":"S Jia","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","article-title":"MicroRNAs in body fluids\u2013the mix of hormones and biomarkers","volume":"8","author":"MA Cortez","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"H Valadi","year":"2007","journal-title":"Nat Cell Biol"},{"issue":"7547","key":"ref15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumour secretomes promote resistance and tumour progression","volume":"520","author":"AC Obenauf","year":"2015","journal-title":"Nature"},{"issue":"29","key":"ref16","doi-asserted-by":"crossref","first-page":"E5930","DOI":"10.1073\/pnas.1705206114","article-title":"BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells","volume":"114","author":"TR Lunavat","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/CMR.0000000000000450","article-title":"Serum exosomal microRNAs as potent circulating biomarkers for melanoma","volume":"28","author":"L Tengda","year":"2018","journal-title":"Melanoma Res"},{"issue":"5543","key":"ref18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.1064921","article-title":"Identification of novel genes coding for small expressed RNAs","volume":"294","author":"M Lagos-Quintana","year":"2001","journal-title":"Science"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s13277-015-4599-0","article-title":"Circulating epigenetic biomarkers in melanoma","volume":"37","author":"Y Xin","year":"2016","journal-title":"Tumour Biol"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.ajpath.2012.07.009","article-title":"miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1","volume":"181","author":"S Liu","year":"2012","journal-title":"Am J Pathol"},{"issue":"30","key":"ref21","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood based markers for cancer detection","volume":"105","author":"PS Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"ref22","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final Version of 2009 AJCC Melanoma Staging and Classification","volume":"27","author":"CM Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"No. 1","key":"ref24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"Vol. 57","author":"Y Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","article-title":"RAS is regulated by the let-7 microRNA family","volume":"120","author":"SM Johnson","year":"2005","journal-title":"Cell"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.radonc.2013.06.032","article-title":"Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g","volume":"108","author":"J Salendo","year":"2013","journal-title":"Radiother Oncol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/CMR.0000000000000140","article-title":"Let-7b overexpression leads to increased radiosensitivity of uveal melanoma cells","volume":"25","author":"Y Zhou","year":"2015","journal-title":"Melanoma Res"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdw007","article-title":"Identification of high-grade serous ovariancancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies","volume":"27","author":"M Petrillo","year":"2016","journal-title":"Ann Oncol"},{"issue":"23","key":"ref29","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1016\/j.febslet.2012.10.014","article-title":"MicroRNA 497 modulates interleukin 1 signalling via the MAPK\/ERK pathway","volume":"586","author":"D Zheng","year":"2012","journal-title":"FEBS Lett"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-09-2721","article-title":"Melanoma MicroRNA signature predicts post-recurrence survival","volume":"16","author":"MF Segura","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12032-010-9797-4","article-title":"miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2","volume":"29","author":"W Zhu","year":"2012","journal-title":"Med Oncol"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1159\/000430172","article-title":"The down-regulation of microRNA-497 contributes to cell growth and cisplatin resistance through PI3K\/Akt pathway in osteosarcoma","volume":"36","author":"XJ Shao","year":"2015","journal-title":"Cell Physiol Biochem"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/0008-5472.CAN-10-4455","article-title":"Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis","volume":"71","author":"JL Hood","year":"2011","journal-title":"Cancer Res"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nm.2753","article-title":"Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET","volume":"18","author":"H Peinado","year":"2012","journal-title":"Nat Med"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"e46874","DOI":"10.1371\/journal.pone.0046874","article-title":"Identifying mRNA, microRNA and protein profiles of melanoma exosomes","volume":"7","author":"D Xiao","year":"2012","journal-title":"PLoS One"},{"issue":"21","key":"ref36","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/cncr.29586","article-title":"Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors","volume":"121","author":"AM Menzies","year":"2015","journal-title":"Cancer"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v2i0.20360","article-title":"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research","volume":"2","author":"KW Witwer","year":"2013","journal-title":"J Extracell Vesicles"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0206942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T08:16:01Z","timestamp":1662365761000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0206942"}},"subtitle":[],"editor":[{"given":"Suzie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0206942","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.17504\/protocols.io.tuienue","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]}}}